FDA approval of two colon cancer therapies triggers discussion among researchers, clinicians about best treatment and clinical trial designs. CMS reimbursement pending; costs to U.S. of the new drugs could be billions per year, but some predict dramatic increases in survival.
Also in this 8-page issue: Tony Hunter, Raymond DuBois win AACR Landon prizes.
Funding opportunities: ASCO breast cancer research award; Lustgarten Foundation prostate cancer research award; NCI program announcements available.
Trending Stories
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- NCI: Cancer center communicators are key to the success of the National Cancer Plan
- Richard Simon, NCI’s visionary biostatistician, dies at 80
- As House prepares cuts for NIH, Rathmell urges Senate to protect funding in FY25
- Are we focused on the wrong risk type in genetic screening?
Breast cancer screening study shows new paths to population screening
